Back to library
Loading…
cognition · The Lancet Neurology · 2024
This study found that late-onset myoclonic epilepsy in Down syndrome (LOMEDS) is a robust and early clinical marker for the onset of Alzheimer's disease in individuals with Down syndrome.
Lage-Martinez A, et al.
This study found that late-onset myoclonic epilepsy in Down syndrome (LOMEDS) is a robust and early clinical marker for the onset of Alzheimer's disease in individuals with Down syndrome.